CBD for Sleep, Stress & Insomnia: What the Evidence Says
Quick Answer
Cannabidiol (CBD) may support sleep by modulating endocannabinoid system (ECS) tone, serotonin 5-HT1A receptor signalling, and hypothalamic-pituitary-adrenal (HPA) axis activity. A 2019 case series by Shannon et al. in The Permanente Journal reported that 66.7% of participants experienced improved sleep scores within the first month of CBD use. However, clinical responses remain variable, evidence quality is mixed, and CBD should be viewed as a complementary support rather than a primary treatment for stress-related sleep disturbance.
CBD does not produce psychoactive effects and is not classified as a sedative or hypnotic. Its effects appear to be regulatory rather than suppressive, making it most relevant where hyperarousal, chronic pain, or anxiety-driven insomnia are contributing factors.
At a Glance
- CBD is a non-intoxicating phytocannabinoid from Cannabis sativa that does not directly activate CB1 or CB2 cannabinoid receptors
- Research by Blessing et al. (2015) in Neurotherapeutics identified preclinical and clinical evidence supporting CBD’s potential anxiolytic properties via serotonin 5-HT1A receptor modulation
- CBD may attenuate cortisol release associated with HPA axis dysregulation, a common driver of stress-related insomnia
- CBD inhibits cytochrome P450 enzymes (CYP3A4, CYP2C19), creating potential drug-drug interactions with antidepressants, benzodiazepines, and anticoagulants
- Clinical outcomes vary based on dose, timing, baseline neurobiology, and whether sleep disturbance is driven by anxiety, pain, or inflammation
- The Therapeutic Goods Administration (TGA) in Australia classifies low-dose CBD as a Schedule 3 medicine, available over the counter since February 2021
Understanding CBD: What It Is and What It Is Not
Cannabidiol (CBD) is one of over 100 phytocannabinoids identified in Cannabis sativa, first isolated by Roger Adams at the University of Illinois in 1940 and structurally characterised by Raphael Mechoulam at the Hebrew University of Jerusalem in 1963. Unlike delta-9-tetrahydrocannabinol (THC), CBD does not produce intoxicating or euphoric effects. Most commercially available CBD products are extracted from hemp varieties containing less than 0.3% THC.
Importantly, CBD is not a sedative, hypnotic, or conventional anxiolytic medication. Its effects appear to be regulatory rather than suppressive, influencing multiple neurobiological systems involved in stress adaptation and sleep-wake balance. The World Health Organization (WHO) concluded in a 2018 critical review that CBD exhibits no effects indicative of abuse or dependence potential.
The Endocannabinoid System and Stress Physiology
The endocannabinoid system (ECS), first described by Allyn Howlett and William Devane in 1988, is a regulatory network involved in maintaining physiological homeostasis across stress responsiveness, emotional regulation, immune signalling, pain perception, and sleep-wake cycling.
CBD does not directly activate cannabinoid receptors (CB1 or CB2). Instead, it appears to influence overall ECS tone by modulating the degradation of endogenous cannabinoids such as anandamide (AEA) through inhibition of fatty acid amide hydrolase (FAAH). Hill et al. (2018) in Nature Reviews Neuroscience detailed how endocannabinoid signalling integrates with the stress response, including cross-talk with serotonin (5-HT1A), gamma-aminobutyric acid (GABA), and transient receptor potential vanilloid 1 (TRPV1) channels.
CBD, Cortisol, and the Stress Response
Chronic psychological stress is associated with dysregulation of the HPA axis and altered diurnal cortisol rhythms, a pattern frequently observed in clinical practice at Elemental Health and Nutrition in Adelaide. Stress-related sleep disturbance is more commonly driven by nervous system hyperarousal and elevated evening cortisol than by a primary sleep disorder.
| Mechanism | Effect of CBD | Clinical Relevance |
|---|---|---|
| HPA axis modulation | May attenuate stress-induced cortisol release | Reduced physiological hyperarousal before sleep |
| 5-HT1A receptor agonism | May reduce anticipatory anxiety | Improved sleep onset latency in anxious individuals |
| FAAH inhibition | May increase anandamide availability | Enhanced endocannabinoid tone and stress buffering |
| GABA modulation | May potentiate GABAergic signalling | Calming effect on overactive neural circuits |
Some experimental and clinical studies, including work by Zuardi et al. (2020) published in the International Journal of Molecular Sciences, suggest CBD may attenuate stress-induced cortisol responses and reduce physiological reactivity in anxiety-provoking situations. These effects are not consistent across individuals and appear to depend on dose, timing, and baseline neurobiology. CBD does not function as a direct hormonal therapy.
CBD and Anxiety-Related Sleep Disturbance
Anxiety disorders affect approximately 3.3 million Australians according to the Australian Bureau of Statistics, and represent a common contributor to sleep-onset insomnia and nocturnal awakenings. Several human studies have reported reductions in subjective anxiety following acute or short-term CBD administration, which may indirectly support sleep initiation in certain individuals.
Blessing et al. (2015), publishing in Neurotherapeutics, reviewed preclinical and human experimental evidence supporting CBD’s potential anxiolytic effects, which appear to involve serotonergic signalling and limbic system modulation (particularly the amygdala and prefrontal cortex) rather than sedation. This profile may be most relevant for individuals experiencing stress-related anxiety and nervous system dysregulation, as explored further in our mental health physiology resources.
CBD and Sleep Quality: What the Evidence Shows
Shannon et al. (2019) conducted a retrospective case series of 72 adults published in The Permanente Journal, reporting that sleep scores improved in 66.7% of participants within the first month of CBD use, though scores fluctuated over time. Research examining CBD and sleep remains limited and heterogeneous across study designs, populations, and outcome measures.
Babson et al. (2017), reviewing the literature in Current Psychiatry Reports, noted that outcomes appear to vary depending on whether sleep disturbance is driven by anxiety, chronic pain, inflammation, or neurological hyperarousal. Notably, CBD does not consistently improve sleep architecture metrics such as slow-wave sleep or REM duration and should not be considered a substitute for investigating underlying drivers of insomnia or non-restorative sleep.
Safety, Interactions, and Clinical Caution
Iffland and Grotenhermen (2017), in a comprehensive safety review published in Cannabis and Cannabinoid Research, reported that CBD is generally well tolerated at doses up to 1,500 mg/day, but it is not without risk.
| Category | Details |
|---|---|
| Common adverse effects | Gastrointestinal discomfort, fatigue, appetite changes, dizziness |
| Enzyme inhibition | CYP3A4, CYP2C19, CYP2C9 (cytochrome P450 family) |
| Medications at risk | Antidepressants (SSRIs, SNRIs), benzodiazepines, antiepileptics, anticoagulants (warfarin) |
| Regulatory status (Australia) | Schedule 3 (pharmacist-only, low-dose) or Schedule 4 (prescription) via TGA |
Brown and Winterstein (2019), publishing in Epilepsy & Behavior, identified 139 potential drug-drug interactions involving CBD. For this reason, CBD should not be used without professional guidance in individuals taking prescription medications or managing complex chronic health conditions.
Practical Considerations (Not Prescriptive Advice)
| Factor | Consideration |
|---|---|
| Product quality | Varies significantly between manufacturers; certificate of analysis (COA) essential |
| Third-party testing | Independent laboratory verification of cannabinoid content, heavy metals, pesticides |
| Dose-response | Clinical responses are dose-dependent and often non-linear (biphasic effect) |
| Individual variation | Sensitivity differs widely based on genetics, body composition, and ECS tone |
| Clinical role | CBD should be considered an adjunct, not a primary intervention |
When CBD May Be Considered
CBD may be explored as part of a broader functional medicine strategy when anxiety, pain, or nervous system hyperarousal contribute to poor sleep — particularly after foundational factors such as sleep hygiene, circadian alignment, magnesium status, and nutrient cofactors have been addressed. VanDolah et al. (2019) in the Mayo Clinic Proceedings provided clinician guidance emphasising the importance of contextualising CBD within a comprehensive care framework rather than using it as a standalone intervention.
Next Steps
- Investigate underlying drivers: At Elemental Health and Nutrition, sleep disturbance is approached as a systems-level issue. Persistent insomnia or non-restorative sleep often reflects deeper physiological dysregulation, including altered stress signalling, inflammatory burden, or metabolic strain.
- Address foundational factors first: Rather than focusing on a single supplement, clinical assessment may include evaluation of stress physiology, circadian rhythm disruption, and drivers commonly associated with chronic fatigue and persistent exhaustion.
- Consider CBD in context: CBD, where appropriate, is considered within this broader clinical context — not as a standalone solution.
Frequently Asked Questions
Key Insights
- CBD may influence stress and sleep indirectly through regulatory neurobiological pathways including the ECS, serotonin 5-HT1A receptors, and HPA axis modulation
- Potential benefits appear most relevant for anxiety-related sleep disturbance rather than primary sleep disorders
- Clinical responses vary significantly between individuals based on dose, timing, and baseline neurobiology
- CBD does not replace appropriate investigation of sleep or fatigue disorders
Citable Takeaways
- Shannon et al. (2019) reported that 66.7% of participants in a 72-person case series experienced improved sleep scores within the first month of CBD use, published in The Permanente Journal
- Blessing et al. (2015) identified preclinical and human evidence supporting CBD’s anxiolytic potential via serotonin 5-HT1A receptor modulation, published in Neurotherapeutics
- CBD inhibits cytochrome P450 enzymes (CYP3A4, CYP2C19), and Brown and Winterstein (2019) identified 139 potential drug-drug interactions involving CBD in Epilepsy & Behavior
- Hill et al. (2018) detailed in Nature Reviews Neuroscience how endocannabinoid signalling integrates with the stress response, supporting the rationale for CBD’s indirect effects on stress-related sleep disturbance
- Iffland and Grotenhermen (2017) reported in Cannabis and Cannabinoid Research that CBD is generally well tolerated at doses up to 1,500 mg/day, though adverse effects including fatigue and gastrointestinal discomfort may occur
- The World Health Organization (2018) concluded in a critical review that CBD exhibits no effects indicative of abuse or dependence potential
Looking for Clinical Guidance in Adelaide?
If you are experiencing persistent stress-related sleep issues or fatigue, a personalised assessment may help clarify the underlying drivers. At Elemental Health and Nutrition, functional medicine care focuses on understanding why sleep disruption is occurring, rather than masking symptoms.
References
- Russo EB. Cannabidiol claims and misconceptions. Trends Pharmacol Sci. 2017 Mar;38(3):198-201. https://doi.org/10.1016/j.tips.2016.12.004
- Hill MN et al. Integrating endocannabinoid signaling and cannabinoids into the biology of stress. Nat Rev Neurosci. 2018 Mar;19(3):151-166. https://doi.org/10.1038/nrn.2018.1
- Campos AC et al. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3364-78. https://doi.org/10.1098/rstb.2011.0384
- Shannon S et al. Cannabidiol in anxiety and sleep: a large case series. Perm J. 2019 Jan;23:18-041. https://doi.org/10.7812/TPP/18-041
- Zuardi AW et al. Cannabidiol for the treatment of anxiety disorders: an update. Int J Mol Sci. 2020 Oct 15;21(20):7681. https://doi.org/10.3390/ijms21207681
- Babson KA et al. Cannabis, cannabinoids, and sleep: a review of the literature. Curr Psychiatry Rep. 2017 Mar;19(4):23. https://doi.org/10.1007/s11920-017-0775-9
- Molero Y et al. Medications for insomnia and risk of mortality: a nationwide cohort study. Sleep Med Rev. 2020 Dec;54:101356. https://doi.org/10.1016/j.smrv.2020.101356
- Hillard CJ. Stress regulates endocannabinoid-CB1 receptor signaling. Semin Immunol. 2014 Jun;26(3):205-11. https://doi.org/10.1016/j.smim.2014.03.003
- Blessing EM et al. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015 Oct;12(4):825-36. https://doi.org/10.1007/s13311-015-0387-1
- Turna J et al. Is cannabis treatment for anxiety, mood, and related disorders ready for prime time? Lancet Psychiatry. 2022 Feb;9(2):98-99. https://doi.org/10.1016/S2215-0366(21)00471-9
- Brown JD, Winterstein AG. Potential adverse drug events and drug-drug interactions with cannabidiol. Epilepsy Behav. 2019 Jul;96:1-9. https://doi.org/10.1016/j.yebeh.2019.04.007
- Iffland K, Grotenhermen F. An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis Cannabinoid Res. 2017;2(1):139-154. https://doi.org/10.1089/can.2016.0034
- VanDolah HJ et al. Clinicians’ guide to cannabidiol and hemp oils. Mayo Clin Proc. 2019 Sep;94(9):1840-1851. https://doi.org/10.1016/j.mayocp.2019.01.003
- Whiting PF et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015 Jun 23-30;313(24):2456-73. https://doi.org/10.1001/jama.2015.6358
- Hoch E et al. Risks associated with the non-medicinal use of cannabis. Dialogues Clin Neurosci. 2019;21(2):149-157. https://doi.org/10.31887/DCNS.2019.21.2/ehoche
